Terns Pharmaceuticals, Inc. — Director's Dealing 2022

Jan 29, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2022-01-26

Reporting Person: Quirk Erin (President, CMO and Head of R&D)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-26	Stock Option (Right to Buy)	$5.36	A	92500	Acquired	2032-01-26	Common Stock (92500)	Direct

Footnotes

F1: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.